Secondary breast angiosarcoma and paclitaxeldependent prolonged disease control: Report of two cases and review of the literature

Donatella Gambini, Roberto Visintin, Elisa Locatelli, Claudia Bareggi, Barbara Galassi, Letterio Runza, Concetta Blundo, Irina Sosnovskikh, Maurizio Tomirotti

Research output: Contribution to journalArticle

Abstract

Secondary breast angiosarcomas are a well-known entity generally characterized by a poor outcome, especially in patients with advanced disease. Among the drugs with demonstrated activity, taxane derivatives are one of the most effective histology-driven treatments against angiosarcomas. We report two cases of secondary breast angiosarcoma, both characterized by a very peculiar behavior towards paclitaxel. Both patients showed local recurrence of angiosarcoma after primary surgery, and they achieved complete remission following treatment with weekly paclitaxel. When a locoregional recurrence was observed as a result of a brief treatment interruption or a treatment delay, a new complete remission was rapidly achieved with the resumption of the drug, without evidence of any significant adverse effects.

Original languageEnglish
Pages (from-to)e60-e63
JournalTumori
Volume101
Issue number2
DOIs
Publication statusPublished - Mar 1 2015

    Fingerprint

Keywords

  • Angiogenesis
  • Paclitaxel
  • Secondary breast angiosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Gambini, D., Visintin, R., Locatelli, E., Bareggi, C., Galassi, B., Runza, L., Blundo, C., Sosnovskikh, I., & Tomirotti, M. (2015). Secondary breast angiosarcoma and paclitaxeldependent prolonged disease control: Report of two cases and review of the literature. Tumori, 101(2), e60-e63. https://doi.org/10.5301/tj.5000252